Botulax is made in Korea by Hugel Pharma. The advantages of Botulax is that Botulax is strictly controlled for safety and high stable potency, has purity of 99% and safety & efficacy have been successfully proved compared with Botox. Botulax contains 100 units (U) of Clostridium botulinum toxin type A, 0.5 milligrams of albumin (human)and 0.9 milligrams of sodium chloride in a sterile, vacuum-dried from without a preservative. Botulax is approved in Thailand and South America, however you need to check your own country import policy, botulax is waitting for FDA approval in the USA, it is in clinical trail process.
It appears as a lyophilized white powder for injection in a colorless transparent vial.
Expire date will be 36 months from the manufacture date.
The unopened lyophilized vial should be stored in a freezer (below -5 degree) or refrigerator (2-8 degree)
Higher specific activity than those of other company’s botolinum toxin products by improving lyophilization process
Botulinum toxin type A neutroxin: purified from Clostridium botulinum type A
Albumin: Human serum albumin,bulking and stabilizing agent and adhesion reducer.
KP grade NaCl: Bulking agent and keeping isotonicity during formulation
KP grade Developmental status:
2007.5: reported nonclinical study
2008.3: reported clinically study Phase l
2009.7: Finished Phase lll clinically study
Facility: GMP approved by KFDA
Excellent Effect – Result appeciable improvement
Simple Procedure – Just by few tiny injections
Short Treatment – 10 minutes, as short as a tea break
No Down Time – Resume normal work right away
Fast Onset- Take only 2 to 3 days to see noticeable effect
Outstanding Efficacy – Over 98% users satisfied with the Botulax® treatments
Proven efficacy & Safety – The efficacy and safety of Botulium Toxin Type A are proved and verified to be comparable to botox in clinical studies.
Global Product – Global Product, Botulium Toxin Type A has been sold in over 25 countries.
Guarateed Safety – Approved by Health Authorities with over 10 years’ clinical practices.
Not just cosmetic Botox, Botulium Toxin Type A also has therapeutic applications, Botulium Toxin Type A is used for the treatment of benign essential blepharspasm in patients 18 years of age and above. For the treatment of equinus foot deformity due to spasticity in pediatric cerebral palsy patients 2 years of age and above. And as many know Botox, for temporary improvement of serious glabellar wrinkles ranging from moderate to severe associated with corrugators muscle and/or procerus muscle activities in adults over the age of 18 and below the age of 65. The vials are generally stored in a freezer or refrigerator and they retain a shelf life of 24 months.
For blepharospasm the initial recommended dose is 1.25 – 2.5 U (0.05 mL to 0.1 mL volume at each site) injected into the medial and lateral pre-tarsal orbicularis oculi of the upper lid and into the lateral pre-tarsal orbicularis oculi of the lower lid. For pediatric cerebral palsy, a total dose of 4U/kg bodyweight is recommended for the affected gastrocnemius muscle in patients with hemiplegia. And in patients with diplegia, the recommended dose is 6U/kg bodyweight divided between both legs. The maximum dose administered must not exceed 200U/patient at a time. For Glabellar wrinkles reconstituted sterile saline. 20U is used and there are additional application instructions for best practice, actual amounts vary on the presentation of the client.
In Blepharospasm, the effects should appear within three days and peak after three weeks. For pediatric cerebral palsy applications, the expectation is improvement within four weeks of the injection. The effects vary for glabellar wrinkles due to the usually individualized dosages.
There is the possibility of reactions at the site of an injection, and effects beyond the injection site, including but not limited to asthenia, generalized muscle weakness, diplopia, ptosis, dysphagia, dysphonia, dysarthria, urinary incontinence and breathing difficulties. Serious hypersensitivity has been reported as rare. There is a caution for people with pre-existing neuromuscular disorders, and for those with corneal exposure and ulceration in blepharospasm. Botulium Toxin Type A is not to be administered at all if a patient has a known allergy to any of the ingredients, or if the patients have neuromuscular junctional disorders or known to have adverse reactions. They should not be administered while taking muscle relaxants and some antibiotics. Further, the actual effects of prolonged use are not entirely explored. There is also additional advice for the specific therapeutic conditions mentioned, as this description is not comprehensive.
In the case of overdose
In the case of an overdose it has been advised that effects may not be immediate. It is further advised that the patient be monitored for muscle weakness and/or paralysis for a period of weeks after the occurrence. There is an anti-toxin available but the caution with the anti-toxin is that it will not reduce any already apparent effects.